A Natural History Study of Fibrodysplasia Ossificans Progressiva (FOP)

• ClinicalTrials.gov Identifier: NCT02322255
• Recruitment Status: Completed
• First Posted: December 23, 2014
• Last Update Posted: June 26, 2020
• Sponsor: Clementia Pharmaceuticals Inc.
• Information provided by (Responsible Party): Ipsen ( Clementia Pharmaceuticals Inc. )

Study Description

Brief Summary:

Fibrodysplasia Ossificans Progressiva (FOP) is a rare, severely disabling disease characterized by painful, recurrent episodes of soft tissue swelling (flare-ups) that result in abnormal bone formation in muscles, tendons, and ligaments. Flare-ups begin early in life and may occur spontaneously or after soft tissue trauma, vaccinations, or influenza infections. Recurrent flare-ups progressively restrict movement by locking joints leading to cumulative loss of function and disability. This 3-year, non-interventional, two-part, natural history study is designed to gain insight into total body HO, FOP disease progression, the impact of FOP on subjects' physical functioning, and clinical features and biomarkers that may be useful in the diagnosis and monitoring of disease progression. This natural history study will also provide important information to inform the design of subsequent interventional trials.

Condition or disease
Fibrodysplasia Ossificans Progressiva

Detailed Description:

This is a multi-center, natural history, non-interventional, longitudinal study in subjects with classic FOP. A thorough baseline examination will be performed to determine the current status of disease in each subject. In Part A, two imaging modalities assessed total body HO at baseline, and the optimal method (low-dose whole body CT scan [excluding head]) will be employed in Part B for the balance of the study. Progression will be assessed at annual in-clinic visits (ie, at Months 12, 24, and 36) at which time the procedures conducted at the baseline visit will be repeated. In addition, site personnel will telephone subjects midway between the annual visits (ie, at Months 6, 18, and 30).

During the 36-month follow-up period, at least one new flare-up (with a maximum of one per year) will be carefully studied. An in-clinic visit will be performed within 14 days following the subject's identification of his/her flare-up. Additional visits at Day 42 and Day 84 (after the initial flare-up clinic visit) will be performed. An additional future visit may be scheduled after Day 84 at the discretion of the Principal Investigator (PI) for prolonged flare-ups. However, subjects with an eligible flare-up may elect to participate in an ongoing Clementia interventional study rather than continue in this natural history study.

Study Design

• Study Type: Observational
• Actual Enrollment: 114 participants
• Observational Model: Case-Only
• Time Perspective: Prospective
• Official Title: A Natural History, Non-Interventional, Two-Part Study in Subjects With Fibrodysplasia Ossificans Progressiva (FOP)
• Actual Study Start Date: December 18, 2014
• Actual Primary Completion Date: April 9, 2020
• Actual Study Completion Date: April 9, 2020

Groups and Cohorts

Group/Cohort
All Subjects; All subjects enrolled in the study.

Outcome Measures

Primary Outcome Measures :

1. Change from baseline in the total body burden of heterotopic ossification as assessed by the optimal imaging modality (low-dose whole body CT [excluding head]). [ Time Frame: Month 36 ]

Secondary Outcome Measures :

1. Change from baseline in physical function as assessed by range of motion. [ Time Frame: Month 12, Month 24, and Month 36 ]
2. Change from baseline in patient-reported use of assistive devices and adaptations. [ Time Frame: Month 6, Month 12, Month 18, Month 24, Month 30, and Month 36 ]
3. Change from baseline in a disease-specific patient-reported outcome measure (FOP-Physical Function Questionnaire [FOP-PFQ]). [ Time Frame: Month 6, Month 12, Month 18, Month 24, Month 30, and Month 36 ]
4. Change from baseline in a patient-reported measure of physical and mental health (PROMIS Global Health Scale). [ Time Frame: Month 6, Month 12, Month 18, Month 24, Month 30, and Month 36 ]
5. Change from baseline in biomarkers. [ Time Frame: Month 12, Month 24, and Month 36 ]
6. Flare-up progression as assessed by the change from baseline in heterotopic ossification at the flare-up site. [ Time Frame: Flare-up initiation, Flare-up Days 42 and 84 ]
7. Flare-up progression as assessed by the change from baseline in pain and swelling at the flare-up site. [ Time Frame: Flare-up initiation, Flare-up Days 42 and 84 ]
8. Flare-up progression as assessed by the change from baseline biomarkers. [ Time Frame: Flare-up initiation, Flare-up Days 42 and 84 ]
9. Flare-up progression as assessed by the change from baseline in physical function as assessed by range of motion. [ Time Frame: Flare-up initiation, Flare-up Days 42 and 84 ]
10. Flare-up progression as assessed by the change from baseline in a disease-specific patient-reported outcome measure (FOP-Physical Function Questionnaire [FOP-PFQ]). [ Time Frame: Flare-up initiation, Flare-up Days 42 and 84 ]
11. Flare-up progression as assessed by the change from baseline in a patient-reported outcome measure of physical and mental health (PROMIS Global Health Scale). [ Time Frame: Flare-up initiation, Flare-up Days 42 and 84 ]

Biospecimen Retention:   Samples With DNA

Blood and urine samples for biomarker and proteomic analysis.

Eligibility Criteria

• Ages Eligible for Study: up to 65 Years (Child, Adult, Older Adult)
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No
• Sampling Method: Non-Probability Sample

Study Population

Individuals with classic FOP (R206H mutation).

Criteria

Inclusion Criteria:

- Subjects clinically diagnosed with classical FOP with documented R206H mutation or believed to carry the R206H mutation

Exclusion Criteria:

- Participation in an interventional clinical research study within the 4 weeks prior to enrollment

Contacts and Locations

Locations

United States, California

University of California San Francisco, Division of Endocrinology and Metabolism

San Francisco, California, United States, 94143

United States, Pennsylvania

University of Pennsylvania, Center for FOP & Related Bone Disorders

Philadelphia, Pennsylvania, United States, 19104

Argentina

Hospital Italiano de Buenos Aires, Department of Pediatrics

Buenos Aires, Argentina

Australia, Queensland

Queensland University of Technology (QUT) Institute of Health and Biomedical Innovation (IHBI)

Woolloongabba, Queensland, Australia, 4102

France

Hôpital Necker-Enfants Malades, Department of Genetics

Paris, France

Italy

Gaslini Institute, Unit of Rare Diseases, Department of Pediatrics

Genoa, Italy

United Kingdom

The Royal National Orthopaedic Hospital, Brockley Hill

Stanmore, Middlesex, United Kingdom, HA7 4LP

Sponsors and Collaborators

Clementia Pharmaceuticals Inc.

Investigators

• Study Director: Ipsen Medical Director; Ipsen

More Information

Additional Information:

website for the International FOP Association 

Click here for more information about this study: A Natural History, Non-Intervention Study in Subjects with Fibrodysplasia Ossificans Progressiva (FOP) 

Publications:

Connor JM, Evans DA. Fibrodysplasia ossificans progressiva. The clinical features and natural history of 34 patients. J Bone Joint Surg Br. 1982;64(1):76-83. doi: 10.1302/0301-620X.64B1.7068725.

Zhang W, Zhang K, Song L, Pang J, Ma H, Shore EM, Kaplan FS, Wang P. The phenotype and genotype of fibrodysplasia ossificans progressiva in China: a report of 72 cases. Bone. 2013 Dec;57(2):386-91. doi: 10.1016/j.bone.2013.09.002. Epub 2013 Sep 17.

Cohen RB, Hahn GV, Tabas JA, Peeper J, Levitz CL, Sando A, Sando N, Zasloff M, Kaplan FS. The natural history of heterotopic ossification in patients who have fibrodysplasia ossificans progressiva. A study of forty-four patients. J Bone Joint Surg Am. 1993 Feb;75(2):215-9. doi: 10.2106/00004623-199302000-00008.

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Warner SE, Kaplan FS, Pignolo RJ, Smith SE, Hsiao EC, De Cunto C, Di Rocco M, Harnett K, Grogan D, Genant HK. Whole-body Computed Tomography Versus Dual Energy X-ray Absorptiometry for Assessing Heterotopic Ossification in Fibrodysplasia Ossificans Progressiva. Calcif Tissue Int. 2021 Dec;109(6):615-625. doi: 10.1007/s00223-021-00877-6. Epub 2021 Jul 31.

Kou S, De Cunto C, Baujat G, Wentworth KL, Grogan DR, Brown MA, Di Rocco M, Keen R, Al Mukaddam M, le Quan Sang KH, Masharani U, Kaplan FS, Pignolo RJ, Hsiao EC. Patients with ACVR1R206H mutations have an increased prevalence of cardiac conduction abnormalities on electrocardiogram in a natural history study of Fibrodysplasia Ossificans Progressiva. Orphanet J Rare Dis. 2020 Jul 29;15(1):193. doi: 10.1186/s13023-020-01465-x.

Towler OW, Shore EM, Kaplan FS. Skeletal malformations and developmental arthropathy in individuals who have fibrodysplasia ossificans progressiva. Bone. 2020 Jan;130:115116. doi: 10.1016/j.bone.2019.115116. Epub 2019 Oct 23.

Pignolo RJ, Baujat G, Brown MA, De Cunto C, Di Rocco M, Hsiao EC, Keen R, Al Mukaddam M, Sang KLQ, Wilson A, White B, Grogan DR, Kaplan FS. Natural history of fibrodysplasia ossificans progressiva: cross-sectional analysis of annotated baseline phenotypes. Orphanet J Rare Dis. 2019 May 3;14(1):98. doi: 10.1186/s13023-019-1068-7. Erratum In: Orphanet J Rare Dis. 2019 May 23;14(1):113.

• Responsible Party: Clementia Pharmaceuticals Inc.
• ClinicalTrials.gov Identifier: NCT02322255
• Other Study ID Numbers: PVO-1A-001
• First Posted: December 23, 2014
• Last Update Posted: June 26, 2020
• Last Verified: June 2020

Keywords provided by Ipsen ( Clementia Pharmaceuticals Inc. ):

Fibrodysplasia Ossificans Progressiva; FOP disease progression; FOP flare-up progression; FOP; Natural History Study; Non-interventional Study; Observational Study; Heterotopic ossification; Clementia; Myositosis Ossificans Progressiva; Munchmeyer's Disease; Palovarotene

Additional relevant MeSH terms:

Myositis Ossificans; Myositis; Muscular Diseases; Musculoskeletal Diseases